The Effect of Pelvic Floor Muscle Training for Urinary Incontinence in Nepalese Women

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorKathmandu University School of Medical Sciences

About this trial

The purpose of the study is to find the effectiveness of Pelvic floor muscle training (PFMT) for urinary incontinence (UI) among Nepalese women. After screening the women who meet the inclusion criteria will be included. Verbal and written consent will be taken from individual participants then the baseline questionnaire data containing socio-demographic variables and questions related to knowledge of UI, PFM and experience with PFMT and ICIQ UI SF will be collected. Then, a women's health physiotherapist will provide education about UI, PFM, PFMT and lifestyle advice. After the education session the randomisation of the participants into either education only (group A) or education plus PFMT (group B) 1:1 by concealed allocation (sealed envelope with A and B). After allocation, the participants will stay in their assigned intervention group for 1 year. After 12 weeks of the supervised intervention again ICIQ UI SF will be administered by a research assistant to both groups. In the 6th month again ICIQ UI SF will be administered by a research assistant to both groups. Finally, in the 12th month again ICIQ UI SF along with self-efficacy and knowledge questions will be assessed to find the effectiveness of the intervention. This data will help in the further development of the protocol or guideline for the Nepalese women.

Eligibility criteria

Qualifiers

Between age of 18-45 years

ICIQ grading above 3

Understand Nepali language

Willing to be included in the study

Disqualifiers

Pregnant

Planning for pregnancy within a 6 months period

Waiting for gynaecological surgery

History of bladder, renal, or uterine cancer

Trial design

Treatments tested in this trial

  • Education
  • Education and PFMT

Treatment groups

136 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Kathmandu University School of Medical Sciences

Lead sponsor

Norwegian University of Science and Technology

Collaborator